Searched for
UCB INC.
Stocks in news: IRFC, Voltas, IDFC First Bank, Alembic Pharma, LupinMarkets declined sharply on Tuesday due to weak global cues, with the Nifty retesting crucial support near 25,400. Several stocks like IRFC...- Indoco Remedies gets USFDA nod to sell generic epilepsy medicineIndoco Remedies has secured approval from the US health regulator for its generic Lacosamide oral solution. This medication is used to trea...
- Seize the opportunity, invest boldly: RBI Guv Sanjay Malhotra"Financial stability and price stability do not inhibit growth. Far from it. They are essential for sustainable growth. I look forward to w...
- Delhi HC allows Google to withdraw its appeal against order on billing systemThe permission came after senior counsel Sajan Poovayya, appearing for Google, sought withdrawal of its appeal on the grounds that the CCI ...
- Entrepreneurs flag lack of ‘credence’ as IAMAI not representing their interests, favouring Big TechThis signals a deepening of the chasm between the interests of global internet majors such as Google and Facebook and that of the local sta...
- UK watchdog looks at Google's proposals for app developers on Play StoreBritain's June investigation raised concerns that Google's complete control over in-app payments unfairly restricted app developers, forcin...
- Market movers: Adani Group stocks get 2 billion reasons to rally furtherAdani Group said Abu Dhabi’s International Holding Company PJSC (IHC) will invest $2 billion as primary capital in three portfolio companie...
- Glenmark gets tentative nod from USFDA for epilepsy drugThe company will market this product upon receiving final approval of Lacosamide Oral solution, 10 Mg/mL.
- Aurobindo gets USFDA nod for epilepsy, arthritis drugsLevetiracetam injection is used for treatment of partial onset seizures, myoclonic seizures in patients with juvenile myoclonic epilepsy, a...
- Glenmark gets tentative US FDA nod for Lacosamide tabletsGlenmark will market this product upon receiving final approval of its Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg ANDA, it added.
- Cipla ends 3% down even as company only Indian firm in race for Kremers UrbanIndia's third largest drug maker posted a net profit of Rs 294.58 crore for the corresponding period of the previous fiscal year.
- Cipla only Indian firm in race for Kremers UrbanIf Cipla is able to close it, the deal, pegged at around $1.3 billion, will eclipse Lupin’s recent $880 million buyout of Gavis Pharma.
- Twelve stocks in focus in Tuesday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- UCB files cases against Ranbaxy, Aurobindo, Glenmark, Sun Pharma, others on patent issueUCB alongwith others has filed separate cases against as many as 15 drug makers for allegedly infringing its patented drug Vimpat.
- Glenmark confirms patent challenge for its generic versions of VIMPAT in the US CourtGlenmark Generics Ltd confirms that it has filed ANDAs for Lacosamide tablets and oral solution with the US drug authorities with a Paragra...
- Lupin gets USFDA nod to market generic anti-epilepsy drugDrug maker Lupin today said it has received final approval from the US health regulator to market a generic version of UCB's Keppra Oral So...
- Lupin gets final US FDA nod for generic anti-epileptic drugLupin is the 5th largest generics player in the US (by prescriptions), the only Asian company to achieve that distinction.
- Glenmark US arm gets USFDA nod for anti-allergy tabletsPharma major Glenmark today said its US arm has received final approval from the US health regulator to market generic Levocetirizine Dihyd...
- StemCyte opens it first UCB stem cell bank of India at ApolloStemCyte Inc, USA, today announced the opening of it's first umblical cord blood(UCB) stem cell banking facility in India, at Apollo Hospit...
- New data backs UCB drug for arthritisNew clinical data endorses the efficacy of UCB SA's experimental drug Cimzia given either fortnightly or monthly, researchers said on Thurs...
Load More
